Endocrinology

Gut Microbiome Composition Can Predict Latent TB in Patients With Diabetes

Researchers explored the links between latent TB infection status, host immunity, and gut microbiota dybiosis in patients with poorly controlled diabetes.

FDA Clears Automated Insulin Dosing App for Patients With Type 1 Diabetes

The prescription-only device works with integrated continuous glucose monitors and alternate controller enabled pumps.

2023 Standards of Care in Diabetes Released

ADA’s Dr Gabbay discusses the top changes to the Standards of Care in Diabetes—2023

New Guideline on Diabetes-Related Hypoglycemia Management Released

Endocrine Society Clinical Practice Guideline examines better ways to manage hypoglycemia in people with diabetes.

Dexcom G7 Continuous Glucose Monitoring System Gets FDA Clearance

Dexcom G7 offers new features with a 60% smaller, discreet wearable patch.

Continuing ACE Inhibitors Despite Potassium Change Can Have Benefits

Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators.

Presence of Glass Particles Prompts Recall of Octreotide Acetate Injection

To date, the Company has not received any reports of adverse reactions related to this recall.

Can SGLT2 and GLP1 Agents Be Cost-Effective First-Line Treatments for Diabetes?

Researchers evaluate the lifetime cost-effectiveness of using SGLT2 inhibitors or GLP1 receptor agonists as first-line treatments for type 2 diabetes.

NIH Study Compares Four Commonly Used Type 2 Diabetes Medications

The multicenter, randomized, controlled GRADE study was designed to compare the effectiveness of 4 major FDA-approved medications.

Noninferiority of Once-Weekly Insulin Icodec Demonstrated in Two T2D Trials

The 26-week ONWARDS 3 and 4 clinical trials evaluated the efficacy and safety of insulin icodec in adults with type 2 diabetes.

Maintaining Weight Loss After Intensive Lifestyle Intervention and Lower CV Risk in Type 2 Diabetes

Researchers sought to determine if the CV effect of intensive lifestyle intervention varies depending on if patient’s can maintain weight loss after the initial intervention.

Insulin Biosimilar Recalled Due to Missing Label on Prefilled Pens

The recalled product does not pertain to the branded interchangeable biosimilar, Semglee (insulin glargine-yfgn).

FDA Extends Review Period for Teplizumab for Type 1 Diabetes Delay

Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.

Obesity in Adolescence Linked to Type 1 Diabetes in Adulthood

Adolescent obesity is correlated with both adult-onset type 1 diabetes and type 2 diabetes.

Obesity-Associated Microvascular and Macrovascular Complications Among Patients With Diabetes

Investigators examined the effect of obesity on microvascular and macrovascular complications among patients with type 1 or type 2 diabetes.

Excessive Body Weight Change Linked to Increased Risk of Cardiovascular Events in Type 2 Diabetes

Investigators sought to determine if an association existed between weight change and major cardiovascular outcomes among patients with type 2 diabetes.

Hormone Therapy Alters Hemostatic and Inflammatory Biomarkers, Increasing CV Risk in Transgender Persons

Investigators evaluated the effect of gender-affirming hormone therapy on markers associated with systemic, endothelial, or adipose tissue-related inflammation, as well as platelet activation and coagulation.

FDA Clears Smartphone App for Insulin Delivery

The updated t:connect mobile app is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery via iOS and Android operating systems.

Certain Oral Anticoagulants Better Than Warfarin in Diabetes With AF

Information linking certain oral anticoagulants and diabetes complications is lacking. Researchers sought to find a connection between diabetic complications, atrial fibrillation.

Osteoporosis Drug Linked to Depression and Anxiety

Studies show a link between depression and osteoporosis. Researchers investigated whether osteoporosis drugs contributed to depression and anxiety.